Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...

A major amendment has prompted the FDA to extend its review of subcutaneous lecanemab as a starting dose for early Alzheimer disease.

Specifically, the FDA is delaying its verdict on once-weekly Leqembi Iqlik (lecanemab) as a starting dose for patients ...

Subcutaneous injections are a routine yet critical nursing skill that demands precision, safety, and confidence. Recent studies show both face-to-face and video-based training improve nurse competence ...

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...

This segment discusses the safety and side effect profiles of intravenous and subcutaneous immunotherapy in advanced melanoma ...

Concizumab-mtci (Alhemo) is approved for hemophilia A or B with inhibitors, offering a subcutaneous alternative to intravenous treatments. The phase 3 explorer7 trial demonstrated an 86% reduction in ...

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...

Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers. Background: The INSIGHT study evaluates feasibility ...

Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster treatment and fewer side effects.

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) ...